Table 3.
Liposomal Anthracyclines and Dexrazoxane Use in the First Year Stratified by Pre-Existing HF
| HL All Patients (n = 3,348) | HL, No Pre-Existing HF (n = 2,911) | HL, Pre-Existing HF (n = 437) | P Value | |
|---|---|---|---|---|
| Doxorubicin (nonliposomal) | 1,886/3,348 (56.3) | 1,730/2,911 (59.4) | 156/437 (35.7) | <0.001a |
| Either doxorubicin or liposomal doxorubicin | 1,903/3,348 (56.8) | 1,746/2,911 (60.0) | 157/437 (35.9) | <0.001a |
| Liposomal doxorubicinb | 48/1,903 (2.5) | 44/1,746 (2.5) | <11/157 (<7)c | 1.00d |
| Dexrazoxaneb | 32/1,903 (1.7) | 28/1,746 (1.6) | <11/157 (<7)c | 0.33d |
| Either liposomal anthracycline or dexrazoxaneb | 79/1,903 (4.2) | 72/1,746 (4.1) | <11/157 (<7)c | 0.84a |
Values are n/N (%).
HF = heart failure; HL = Hodgkin lymphoma.
a
P values were estimated using the chi-square test.
b
Among patients treated with any anthracycline or liposomal anthracycline in the first year. The denominator includes doxorubicin and liposomal doxorubicin.
c
Cell counts with values <11 were suppressed to avoid reidentification of patients according to Surveillance, Epidemiology, and End Results and Medicare policy.
d
P values were estimated using the Fisher exact test.